Genekor on spetsialiseerunud molekulaargeneetikale.
Meie ettevõte annab arstile kõik tõhusad molekulaarteaduse tööriistad, et abistada neid diagnoosimisel, prognoosi seadmisel ja personaalse ravi pakkumisel patsientidele onkoloogia, kardioloogia, neuroloogia ja farmakogeneetika valdkonnas, kasutades tipptasemel tehnoloogiat ning teaduspõhiseid teadmisi ja kogemusi.
Genekor on 2007. aastal asutatud rahvusvaheline ettevõte, mis tegutseb molekulaarbioloogia ja geneetika valdkonnas. GeneKor juhib tipptasemel seadmetega üleilmset molekulaarbioloogia laborite võrgustikku ning selle põhitegevus on molekulaaranalüüside arendamine ja tegemine.
Teeme oma akrediteeritud laborites mitmeid sertifitseeritud molekulaaruuringuid molekulaargeneetilisi teenuseid, kasutades tipptasemel tehnoloogiat patsientide diagnoosimiseks, prognoosimiseks ja individuaalseks raviks. Genekoris tehtavad testid võimaldavad arstidel kasutada oma patsientide puhul personaalmeditsiini.
Keskendume onkoloogiale, kardioloogiale, neuroloogiale ja farmakogenoomikale. Meie eesmärk on välja töötada kõige selgem, õigem ja kulutõhusam diagnostiline protseduur patsientide ravitulemuste parandamiseks.
Patsiendid kogu maailmas
Riigid
Arstid
Kliinikud
Teaduspublikatsioonid
Angeliki Meintani, Mustafa Ozdogan, Nikolaos Touroutoglou, Konstantinos Papazisis, Ioannis Boukovinas, Cemil Bilir, Stylianos Giassas, Tansan Sualp, Sahin Lacin, Jinga Dan Corneliu, Paraskevas Kosmidis, Tahsin Ozatli, Dimitrios Ziogas, Maria Theochari, Konstantinos […]
Nikolaos Tsoulos1, Konstantinos Agiannitopoulos1, Kevisa Potska1, Anastasia Katseli1, Christina Ntogka1, Georgia Pepe1, Dimitra Bouzarelou1, Athanasios Papathanasiou1, Dimitrios Grigoriadis1, Georgios N. Tsaousis1, Helen Gogas2, Theodore Troupis3, Konstantinos Papazisis4, Ioannis Natsiopoulos5, Vassileios […]
CHRISTOS MARKOPOULOS1, NIKOLAOS TSOULOS2, KONSTANTINOS AGIANNITOPOULOS2 and EVANGELIA KARAGIANNI3
P113_Li-Fraumeni_Genetic testing of Breast_ovarian cancer patients unmask familial pathogenic germline variants in TP53 gene_Clinical implications and family counselling
P075_The Benefits of comprehensive NGS Panels using Liquid Biopsy in Breast Cancer
P051_Exploring the clinical utility of Oncotype DX in ER+HER2-, N0 and N1 breast cancer patients Insights from a Romanian cohort
P050_Genomic risk assessment with Oncotype DX in young women (age ≤ 40 years old) with early-stage ER+HER2-N0 breast cancer
P049_The prognostic role of Ki-67 in relation to Oncotype DX Recurrence Score
P044_Examining the Correlation and Concordance Between Ki-67 Expression and Oncotype DX Recurrence Score_Findings from a Multicenter Study in Turkey
PR status cannot predict Oncotype DX Recurrence Score®: a study in a Greek cohort of N0M0/ER+/PR-/HER2- breast cancer patients tested with Oncotype DX
The prognostic and predictive value of Oncotype DX® in ER+/HER2-/pT2N0, cM0 Breast Cancer Patients
The importance of pre- and post-genetic counselling for genetic testing in hereditary cancer
Low level constitutional mosaicism in breast cancer patients
MAPPING OF GENE VARIANTS IN 7,587 SUBJECTS REFERRED FOR HEREDITARY CANCER
Polygenic Risk Score in a cohort of 105 Breast Cancer patients previously tested with a multi gene panel for hereditary cancer
Next Generation Sequencing (NGS) for the identification of PARP inhibitors’ predictive biomarkers.
Cascade genetic testing utilized only in 31% of initial families with pathogenic variants in breast cancer genes
Copy Number Variations (CNVs) and Hereditary Breast Cancer
Multigene panel testing results for hereditary breast cancer - ESMO 2019
Tumor Mutational Burden TMB - poster at ECCB 2018
Analysis of hereditary cancer syndromes by use of a panel of genes: More answers than questions
BRCA Early Access program - poster at ECP
CTRC-AACR San Antonio Breast Cancer Symposium 2014
St. Gallen 2013 OncotypeDX
St. Gallen 2013 BRCA
EANO 2012
ASCO 2012 EGFR
ASCO 2012 ALK
St. Gallen 2011
ESMO 2011 ALK
ESMO 2011 EGFR